IMMIXBIO N-GENIUS CELL THERAPY PLATFORM

Our N-GENIUS platform, with EXPAND technology, has produced our pioneering lead candidate, CAR-T NXC-201, which has demonstrated an enhanced tolerability profile with the potential to reduce hospitalizations.

Our N-GENIUS platform enables our CAR-Ts to have distinct advantages including: preliminary clinical data — high overall response rate and durable responses; differentiated tolerability profile, resulting in a potential market first “Outpatient CAR-T” in NXC-201; and opportunity to treat a broader group of cancer patients.

Our N-GENIUS cell therapy platform, which has produced NXC-201, consists of three key elements: (1) purpose-built cell therapy evidence capture engine + relational database, which relates ImmixBio internal data to external to accelerate therapy design, manufacture, and preclinical; (2) proprietary EXPAND technology, which is applied to multiple cell therapy indications, already utilized to create NXC-201, to potentially increase efficacy and tolerability; and (3) atomized, novel binding scaffold generation engine, which allows us to make the correct binding for every molecule. We believe key characteristics of NXC-201 may apply to other products candidates produced by the N-GENIUS Platform. Those 3 key characteristics are: (a) high transduction efficiency (lower dose may lead to lower toxicity), (b) low tonic signaling (lower off-target toxicity may lead to lower toxicity), and (c) anti-exhaustion capability (increased persistence may lead to efficacy over an extended period of time).